Immuneering Corporation appoints Michael Bookman as general counsel
Michael Bookman (pictured) has been appointed as general counsel and corporate secretary at Immuneering Corporation, a private biopharmaceutical company. In this newly created role, Bookman will be a member of the executive management team and will oversee the legal strategy, legal compliance, litigation, and regulatory matters. As general counsel, he will support Immuneering’s board of directors in developing and maintaining best practices in governance policies and procedures.
Bookman joins Immuneering from Frequency Therapeutics, where he served as general counsel. Prior to his time at Frequency, Michael was an associate at Latham & Watkins international law firm.
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process.